This inventor holds 1 USPTO granted patent. Top assignees: University of Virginia Patent Foundation, Wisconsin Alumni Research Foundation. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1,045 
1 out of 4,243 
Years Active: 2026
Title: Nisakorn Yodsanit: Inventor in Local Drug Delivery
Introduction
Nisakorn Yodsanit is an inventor associated with Madison, Wisconsin. His patent work addresses a method for delivering drugs locally to help prevent intimal hyperplasia, a condition involving abnormal thickening of the inner lining of blood vessels.
Latest Patents
Yodsanit is associated with 1 patent, titled “Adventitial Painting Modality of Local Drug Delivery to Abate Intimal Hyperplasia.” The disclosure describes adhesive unimolecular micelles, including micelles with NHS or sulfo-NHS terminal groups, and compositions and methods for using them. The micelles may carry fluorescent labels or therapeutic drugs and are described as biocompatible, non-toxic, and non-inflammatory. The approach is designed for rapid operating-room use, including direct application by penbrush painting, and may be implemented without hydrogel.
Career Highlights
Yodsanit’s patent-related affiliations include the University of Virginia Patent Foundation and the Wisconsin Alumni Research Foundation. These organizations support the development and management of university-associated inventions and intellectual property.
Collaborations
His listed collaborators include Kenneth Craig Kent and Lian-Wang Guo. Their shared work is connected to research on local drug delivery and approaches to reducing intimal hyperplasia.
Conclusion
Nisakorn Yodsanit’s patent work focuses on a practical, locally applied drug-delivery approach intended to help address intimal hyperplasia.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile